WHO issues first guideline on GLP-1 drugs for obesity
Why in the news
The World Health Organization released its first global guideline on GLP-1 therapies for treating obesity in adults. It also warned that high prices and limited supply could widen health inequalities.
Key facts
- The guideline targets adults with a BMI of 30 or more; pregnant women are excluded.
- Three medicines are covered: semaglutide, tirzepatide and liraglutide.
- Use must be combined with a healthy diet and regular physical activity.
- These medicines achieve around 15-20% weight loss, comparable to bariatric surgery.
- The guideline makes two conditional recommendations: GLP-1 use for long-term management, and lifestyle change alongside medication.
| Item | Figure |
|---|---|
| People living with obesity worldwide | Over 1 billion |
| Obesity deaths in 2024 | 3.7 million |
| Eligible people likely to get GLP-1 drugs by 2030 | Under 10% |
| Projected annual economic cost by 2030 | USD 3 trillion |
About obesity thresholds
WHO defines adult obesity as a BMI of 30 or above, while India uses a lower threshold of 25. NFHS-5 (2019-21) found 24% of women and 23% of men were overweight or obese.
Exam angle
- Note the three drug names and the BMI cut-off of 30.
- Access barriers are manufacturing capacity and pricing.
- Expect statements on the USD 3 trillion cost and the 10% access figure.